Adam Perlman is Co-Chair of the firm’s Patent Litigation practice and focuses his practice on intellectual property disputes and other complex civil litigation. He has served as lead counsel in major patent litigations in numerous district courts around the country, and has extensive experience serving as lead appellate counsel before the Federal Circuit. He has also litigated inter partes review proceedings before the USPTO. His patent litigation practice has had a particular emphasis on representing brand-name pharmaceutical manufacturers in Hatch-Waxman litigation, and he has tried eight Hatch-Waxman cases to judgment. Beyond Hatch-Waxman cases, his practice has involved a wide range of technologies, including pharmaceuticals, biotechnology, medical devices, computers, and financial services. He has also litigated claims of misappropriation of trade secrets in connection with a patent and licensing dispute involving antibody technology, and in a dispute between mobile phone carriers.
In each of the last two years, Adam has been named “Hatch-Waxman Litigator of the Year – Branded” by LMG Life Sciences. He was named a finalist for the same award for 2018. In 2017, Adam was also named an “Intellectual Property Trailblazer” by The National Law Journal. In 2018 and 2016, Adam was nominated by Managing IP for “Outstanding IP Litigator” for D.C. He has been recognized as a “Life Science Star” by LMG Life Sciences (2012- 2017), and an “IP Star” by Managing IP (2013- 2018). He has been recognized in the 2014 - 2018 editions of IAM 1000 - The World’s Leading Patent Practitioners and was described in the 2018 edition as being “incredibly clever” and as the lead on the “most complex and crucial life sciences suits.” Prior to turning 40, he was named one of the country’s top five intellectual property partners under 40 by Law360. He has also been recognized as a leading attorney appearing before the Federal Circuit by the 2018 edition of IAM 1000 and was listed in the 2014 edition of The Legal 500 as having a “superb reputation” in the appellate field.
Outside of the intellectual property area, Adam’s practice has included SEC, DOJ, and internal investigations relating to alleged FCPA violations involving operations in South America and Eastern Europe. He has litigated commercial disputes in areas including fraud, RICO, contract, and various business torts, and has also represented newspapers, magazines, television networks, and motion picture studios in defamation and other media-related litigation.
Last updated October 2018